Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moleculin Biotech (MBRX) Non-Current Assets (2016 - 2025)

Moleculin Biotech (MBRX) has 10 years of Non-Current Assets data on record, last reported at $12.5 million in Q3 2025.

  • For Q3 2025, Non-Current Assets rose 5.77% year-over-year to $12.5 million; the TTM value through Sep 2025 reached $48.4 million, up 1.95%, while the annual FY2024 figure was $11.7 million, 1.78% down from the prior year.
  • Non-Current Assets reached $12.5 million in Q3 2025 per MBRX's latest filing, roughly flat from $12.5 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $12.5 million in Q2 2025 and bottomed at $11.5 million in Q1 2022.
  • Average Non-Current Assets over 5 years is $11.8 million, with a median of $11.8 million recorded in 2024.
  • Peak YoY movement for Non-Current Assets: dropped 2.2% in 2021, then rose 5.77% in 2025.
  • A 5-year view of Non-Current Assets shows it stood at $11.6 million in 2021, then increased by 2.01% to $11.8 million in 2022, then rose by 1.0% to $11.9 million in 2023, then dropped by 1.78% to $11.7 million in 2024, then rose by 6.28% to $12.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Assets were $12.5 million in Q3 2025, $12.5 million in Q2 2025, and $11.7 million in Q1 2025.